X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2381) 2381
Newsletter (56) 56
Magazine Article (45) 45
Newspaper Article (13) 13
Book Chapter (3) 3
Transcript (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Government Document (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1926) 1926
naproxen (1334) 1334
female (1160) 1160
male (1098) 1098
naproxen - adverse effects (974) 974
middle aged (824) 824
anti-inflammatory agents, non-steroidal - adverse effects (814) 814
adult (803) 803
naproxen - therapeutic use (677) 677
aged (650) 650
index medicus (648) 648
double-blind method (496) 496
anti-inflammatory agents, non-steroidal - therapeutic use (490) 490
nonsteroidal antiinflammatory drugs (441) 441
pharmacology & pharmacy (441) 441
celecoxib (348) 348
osteoarthritis (315) 315
nonsteroidal anti-inflammatory drugs (313) 313
ibuprofen (299) 299
naproxen - administration & dosage (298) 298
medicine, general & internal (284) 284
treatment outcome (277) 277
adolescent (271) 271
anti-inflammatory agents, non-steroidal - administration & dosage (267) 267
risk factors (258) 258
osteoarthritis - drug therapy (255) 255
rofecoxib (252) 252
arthritis, rheumatoid - drug therapy (249) 249
rheumatoid-arthritis (248) 248
aspirin (238) 238
pain (234) 234
animals (233) 233
cyclooxygenase inhibitors - adverse effects (231) 231
double-blind (228) 228
risk (226) 226
clinical trials as topic (224) 224
rheumatology (204) 204
drug therapy (196) 196
arthritis (195) 195
dose-response relationship, drug (175) 175
diclofenac (174) 174
aged, 80 and over (173) 173
drugs (170) 170
efficacy (165) 165
cox-2 inhibitors (163) 163
time factors (160) 160
diclofenac - adverse effects (156) 156
drug therapy, combination (156) 156
cyclooxygenase inhibitors - therapeutic use (155) 155
gastrointestinal toxicity (154) 154
sulfonamides - adverse effects (154) 154
research (149) 149
nsaids (148) 148
care and treatment (147) 147
gastrointestinal diseases - chemically induced (145) 145
ibuprofen - adverse effects (143) 143
analysis (137) 137
aspirin - adverse effects (136) 136
naproxen - pharmacology (135) 135
analgesics (134) 134
lactones - adverse effects (133) 133
cyclooxygenase 2 inhibitors - adverse effects (132) 132
gastroenterology & hepatology (132) 132
naproxen sodium (132) 132
clinical neurology (128) 128
clinical trials (126) 126
pain measurement (122) 122
pain - drug therapy (121) 121
safety (120) 120
medicine & public health (116) 116
placebo (115) 115
migraine (114) 114
cardiovascular diseases - chemically induced (113) 113
inflammation (113) 113
prospective studies (113) 113
sulfonamides - therapeutic use (113) 113
anti-inflammatory agents, non-steroidal - pharmacology (112) 112
randomized controlled trials as topic (109) 109
dosage and administration (104) 104
drug interactions (102) 102
complications and side effects (101) 101
young adult (101) 101
acetaminophen (100) 100
ibuprofen - therapeutic use (100) 100
administration, oral (99) 99
aspirin - therapeutic use (98) 98
prevention (98) 98
rats (98) 98
migraine disorders - drug therapy (97) 97
sulfones - adverse effects (97) 97
drug administration schedule (95) 95
indomethacin (93) 93
diclofenac - therapeutic use (91) 91
internal medicine (90) 90
rheumatoid arthritis (89) 89
therapy (87) 87
management (86) 86
nsaid (86) 86
child (83) 83
cyclooxygenase 2 inhibitors - therapeutic use (83) 83
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2374) 2374
German (38) 38
French (20) 20
Spanish (15) 15
Italian (12) 12
Japanese (9) 9
Norwegian (9) 9
Danish (7) 7
Dutch (7) 7
Russian (6) 6
Polish (5) 5
Hebrew (3) 3
Hungarian (3) 3
Swedish (3) 3
Chinese (2) 2
Czech (1) 1
Korean (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2017, Volume 2019, Issue 10, p. CD012537
Background Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health... 
2019 3.6 All/Other/Non‐cancer chronic pain | Management in children | Anti‐Inflammatory Agents, Non‐Steroidal | Methoxsalen | 2019 3. Chronic pain | Lactones | Arthritis, Juvenile | Chronic non‐cancer pain management | Naproxen | Ibuprofen | Thiazoles | Child health | Management and prevention of chronic non‐cancer pain in children | Sulfones | Chronic Pain | Fenoprofen | Meloxicam | Aspirin | Thiazines | Celecoxib | Pain & anaesthesia | Arthritis, Rheumatoid | Randomized Controlled Trials as Topic | Chronic non‐cancer pain | Medicine General & Introductory Medical Sciences | Chronic Disease | IBUPROFEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | FIBROMYALGIA | SAFETY | TREATMENT OUTCOMES | JUVENILE RHEUMATOID-ARTHRITIS | CLINICAL-TRIALS | GRADE | NAPROXEN | SHORT-TERM | Ibuprofen - therapeutic use | Sulfones - therapeutic use | Thiazines - therapeutic use | Humans | Thiazines - adverse effects | Sulfones - adverse effects | Child, Preschool | Thiazoles - therapeutic use | Thiazoles - adverse effects | Arthritis, Juvenile - drug therapy | Fenoprofen - therapeutic use | Arthritis, Rheumatoid - drug therapy | Aspirin - adverse effects | Aspirin - therapeutic use | Fenoprofen - adverse effects | Child | Celecoxib - adverse effects | Naproxen - adverse effects | Chronic Pain - drug therapy | Celecoxib - therapeutic use | Lactones - adverse effects | Methoxsalen - therapeutic use | Naproxen - therapeutic use | Lactones - therapeutic use | Methoxsalen - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adolescent | Ibuprofen - adverse effects
Journal Article
by Baigent, Colin and Bhala, N and Emberson, J and Merhi, A and Abramson, S and Arber, N and Baron, J.A and Bombardier, C and Cannon, C and Farkouh, M.E and FitzGerald, G.A and Goss, P and Halls, H and Hawk, E and Hawkey, C and Hennekens, C and Hochberg, M and Holland, L.E and Kearney, P.M and Laine, L and Lanas, A and Lance, P and Laupacis, A and Oates, J and Patrono, C and Schnitzer, T.J and Solomon, S and Tugwell, P and Wilson, K and Wittes, J and Adelowo, O and Aisen, P and Al-Quorain, A and Altman, R and Bakris, G and Baumgartner, H and Bresee, C and Carducci, M and Chang, D.-M and Chou, C.-T and Clegg, D and Cudkowicz, M and Doody, L and Miedany, Y.El and Falandry, C and Farley, J and Ford, L and Garcia-Losa, M and Gonzalez-Ortiz, M and Haghighi, M and Hala, M and Iwama, T and Jajic, Z and Kerr, D and Kim, H.-S and Kohne, C and Koo, B.-K and Martin, B and Meinert, C and Muller, N and Myklebust, G and Neustadt, D and Omdal, R and Ozgocmen, S and Papas, A and Patrignani, P and Pelliccia, F and Roy, V and Schlegelmilch, I and Umar, A and Wahlstrom, O and Wollheim, F and Yocum, S and Zhang, X.Y and Hall, E and McGettigan, P and Midgley, R and Moore, R.A and Philipson, R and Curtis, S and Reicin, A and Bond, J and Moore, A and Essex, M and Fabule, J and Morrison, B and Tive, L and Bhala, N and Davies, K and Emberson, J and Halls, H and Holland, L.E and Kearney, P.M and Merhi, A and Patrono, C and Wilson, K and Yau, F and unav and Coxib and traditional NSAID Trialists' (CNT) Collaboration and Coxib Traditional NSAID Trialists
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 769 - 779
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 26, pp. 2519 - 2529
... effects. 2 Evidence of adverse cardiovascular outcomes in a placebo-controlled trial resulted in the withdrawal of the selective COX-2 inhibitor rofecoxib in 2004. 3 On... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2004, Volume 364, Issue 9435, pp. 675 - 684
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2006, Volume 113, Issue 25, pp. 2906 - 2913
Background-The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs ( NSAIDs) have been associated with... 
Drugs | Myocardial infarction | Cyclooxygenase-2 inhibitors | Mortality | Nonsteroidal antiinflammatory drugs | CARDIAC & CARDIOVASCULAR SYSTEMS | drugs | CARDIOVASCULAR EVENTS | myocardial infarction | CONVERTING ENZYME-INHIBITORS | CELECOXIB | BLOOD-PRESSURE | nonsteroidal antiinflammatory drugs | mortality | CYCLO-OXYGENASE-2 INHIBITORS | ROFECOXIB | PERIPHERAL VASCULAR DISEASE | NAPROXEN | OSTEOARTHRITIS | BETA-BLOCKERS | cyclooxygenase-2 inhibitors | Ibuprofen - therapeutic use | Multivariate Analysis | Recurrence | Sulfones - therapeutic use | Confidence Intervals | Myocardial Infarction - mortality | Pyrazoles - therapeutic use | Patient Readmission | Humans | Middle Aged | Sulfones - adverse effects | Male | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Female | Registries | Retrospective Studies | Odds Ratio | Pyrazoles - adverse effects | Diclofenac - therapeutic use | Diclofenac - adverse effects | Risk Factors | Proportional Hazards Models | Celecoxib | Lactones - adverse effects | Lactones - therapeutic use | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Myocardial Infarction - drug therapy | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Denmark | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2012, Volume 7, Issue 4, p. e35196
.... In the present study we examined the effects of two novel NSAIDs and two commonly used NSAIDs in models in which mucosal defence was expected to be impaired... 
ULCERS | ENTERIC-COATED ASPIRIN | SMALL-BOWEL INJURY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | MULTIDISCIPLINARY SCIENCES | NITRIC-OXIDE | PROTON PUMP INHIBITORS | GASTRIC-ULCERATION | HYDROGEN-SULFIDE | NO-NAPROXEN | CYCLOOXYGENASE 1 | Naproxen - analogs & derivatives | Pyrazoles - therapeutic use | Obesity - drug therapy | Rats, Wistar | Hypertension - drug therapy | Male | Nitrates - adverse effects | Nitrates - therapeutic use | Aspirin - adverse effects | Gastric Mucosa - drug effects | Aspirin - therapeutic use | Drug Therapy, Combination | Pyrazoles - adverse effects | Naproxen - adverse effects | Rats, Inbred SHR | Omeprazole - therapeutic use | Rats | Gastrointestinal Tract - drug effects | Omeprazole - adverse effects | Celecoxib | Naproxen - therapeutic use | Rats, Zucker | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Sulfonamides - adverse effects | Gastrointestinal Diseases - chemically induced | Hypertension | Hydrogen sulfide | Omeprazole | COX-2 inhibitors | Aspirin | Nitric oxide | Naproxen | Arthritis | Nonprescription drugs | Sulfide | Drugs | Animal models | Toxicity | Hydrogen | Mucosa | Bleeding | Prostaglandin endoperoxide synthase | Na+/Ca2+-exchanging ATPase | Intestine | Rodents | Older people | Gastroenterology | Bacteria | Trends | Nonsteroidal anti-inflammatory drugs | Damage | Drug dosages | Hydrogen ion concentration | Medical research | Inflammation | Medical screening | Patients | Anti-inflammatory agents | Ulcers | Health risk assessment | Geriatrics
Journal Article
Gastroenterology, ISSN 0016-5085, 2007, Volume 132, Issue 2, pp. 498 - 506
Background & Aims: Traditional nonaspirin, nonsteroidal anti-inflammatory drugs (tNSAIDs) have been associated with a 3- to 5-fold increased risk in upper... 
Gastroenterology and Hepatology | SELECTIVE CYCLO-OXYGENASE-2 INHIBITORS | VARIABILITY | TRIALS | METAANALYSIS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HEMORRHAGE | ULCER | ROFECOXIB | NAPROXEN | ARTHRITIS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Peptic Ulcer Perforation - chemically induced | Half-Life | Warfarin - adverse effects | Duodenal Ulcer - chemically induced | Case-Control Studies | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Drug Interactions | Time Factors | Aspirin - adverse effects | Duodenal Ulcer - epidemiology | Retrospective Studies | Steroids - adverse effects | Stomach Ulcer - chemically induced | Risk Assessment | Cyclooxygenase 2 Inhibitors - administration & dosage | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Anticoagulants - adverse effects | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Delayed-Action Preparations - adverse effects | Stomach Ulcer - epidemiology | Upper Gastrointestinal Tract - drug effects | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Peptic Ulcer Hemorrhage - epidemiology | United Kingdom - epidemiology | Gastrointestinal Diseases - chemically induced | Cohort Studies | Complications and side effects | Nonsteroidal anti-inflammatory drugs
Journal Article